Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MJFF grants Rhythm $1.35M for Phase II Parkinsonís trial
October 2013
SHARING OPTIONS:

BOSTONóRhythm has announced the receipt of a $1.35 million research grant from The Michael J. Fox Foundation for Parkinson's Research to help fund a Phase II clinical trial of RM-131, Rhythm's novel ghrelin agonist for the treatment of refractory constipation in Parkinson's patients. More than 50 percent of Parkinson's disease patients present with moderate to severe constipation, and related gastrointestinal dysfunction can affect the upper gastrointestinal tract as well, causing gastroparesis.  
 
"Refractory constipation is a significant issue in Parkinson's disease, and this first study of RM-131 in Parkinson's patients is focused on this disorder," said Dr. Rhythm CEO Keith Gottesdiener. "As we continue our work to advance RM-131 in the clinic, we are excited to join with The Michael J. Fox Foundation to address this important unmet need in Parkinson's disease."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.